DANIELLE THREATTS: Open Payments
NPI 1033465778 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,811 in 81 payments from 15 companies in 2025. Trend: 2023 $2,657 · 2024 $2,184 · 2025 $2,811
Food & beverage: $2,811
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $611 |
| Otsuka America Pharmaceutical, Inc. | 12 | $462 |
| Vanda Pharmaceuticals Inc. | 12 | $423 |
| Alkermes, Inc. | 8 | $253 |
| Axsome Therapeutics, Inc. | 5 | $193 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $179 |
| Teva Pharmaceuticals USA, Inc. | 3 | $160 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Corium, LLC | 9 | $120 |
Products named: VRAYLAR, FANAPT, REXULTI, Auvelity, CAPLYTA, ARISTADA, ABILIFY MAINTENA, UZEDY.
Industry payments across LA — which companies pay providers there.
